## Elliot B Tapper

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2796572/publications.pdf

Version: 2024-02-01

265 9,229 47
papers citations h-inde

47 84 h-index g-index

274 all docs

274 docs citations

274 times ranked 9235 citing authors

#	Article	IF	CITATIONS
1	Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis. Clinical Gastroenterology and Hepatology, 2020, 18, 2650-2666.	4.4	580
2	Mortality due to cirrhosis and liver cancer in the United States, 1999-2016: observational study. BMJ: British Medical Journal, 2018, 362, k2817.	2.3	557
3	Advancing the global public health agenda for NAFLD: a consensus statement. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 60-78.	17.8	330
4	Use of Liver Imaging and Biopsy in Clinical Practice. New England Journal of Medicine, 2017, 377, 756-768.	27.0	280
5	Malnutrition, Frailty, and Sarcopenia in Patients With Cirrhosis: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology, 2021, 74, 1611-1644.	7.3	263
6	Increased Risk for Hepatocellular Carcinoma Persists Up to 10 Years After HCV Eradication in Patients With Baseline Cirrhosis or High FIB-4 Scores. Gastroenterology, 2019, 157, 1264-1278.e4.	1.3	252
7	Joint American Academy of Dermatology–National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. Journal of the American Academy of Dermatology, 2020, 82, 1445-1486.	1.2	184
8	Rates of and Reasons for Hospital Readmissions in Patients WithÂCirrhosis: A Multistate Population-based Cohort Study. Clinical Gastroenterology and Hepatology, 2016, 14, 1181-1188.e2.	4.4	166
9	A North American Expert Opinion Statement on Sarcopenia in Liver Transplantation. Hepatology, 2019, 70, 1816-1829.	7.3	163
10	Standard assessments of frailty are validated predictors of mortality in hospitalized patients with cirrhosis. Hepatology, 2015, 62, 584-590.	7.3	156
11	The COVID-19 pandemic will have a long-lasting impact on the quality of cirrhosis care. Journal of Hepatology, 2020, 73, 441-445.	3.7	155
12	The high burden of alcoholic cirrhosis in privately insured persons in the United States. Hepatology, 2018, 68, 872-882.	7.3	154
13	FibroScan (Vibration-Controlled Transient Elastography): Where Does It Stand in the United States Practice. Clinical Gastroenterology and Hepatology, 2015, 13, 27-36.	4.4	133
14	Refining the Ammonia Hypothesis. Mayo Clinic Proceedings, 2015, 90, 646-658.	3.0	127
15	A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2016, 14, 753-759.	4.4	124
16	Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 274-282.	17.8	124
17	The Performance of Vibration Controlled Transient Elastography in a US Cohort of Patients With Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2016, 111, 677-684.	0.4	122
18	The Incidence and Outcomes of Ischemic Hepatitis: A Systematic Review with Meta-analysis. American Journal of Medicine, 2015, 128, 1314-1321.	1.5	113

#	Article	IF	CITATIONS
19	Baseline Factors Associated With Improvements in Decompensated Cirrhosis After Direct-Acting Antiviral TherapyAfor Hepatitis C Virus Infection. Gastroenterology, 2018, 154, 2111-2121.e8.	1.3	110
20	The Risks of Thromboembolism Vs. Recurrent Gastrointestinal Bleeding after Interruption of Systemic Anticoagulation in Hospitalized Inpatients With Gastrointestinal Bleeding: A Prospective Study. American Journal of Gastroenterology, 2015, 110, 328-335.	0.4	102
21	Administrative Coding in Electronic Health Care Recordâ€Based Research of NAFLD: An Expert Panel Consensus Statement. Hepatology, 2021, 74, 474-482.	7.3	102
22	Review article: the diagnostic approach and current management of chylous ascites. Alimentary Pharmacology and Therapeutics, 2017, 46, 816-824.	3.7	97
23	Projected increase in obesity and nonâ€alcoholicâ€steatohepatitis–related liver transplantation waitlist additions in the United States. Hepatology, 2019, 70, 487-495.	7.3	96
24	Development of Quality Measures in Cirrhosis by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology, 2019, 69, 1787-1797.	7.3	92
25	Levels of Alanine Aminotransferase Confound Use of Transient Elastography to Diagnose Fibrosis in Patients With Chronic Hepatitis C Virus Infection. Clinical Gastroenterology and Hepatology, 2012, 10, 932-937.e1.	4.4	89
26	Projected prevalence and mortality associated with alcohol-related liver disease in the USA, 2019–40: a modelling study. Lancet Public Health, The, 2020, 5, e316-e323.	10.0	87
27	Important Unresolved Questions in the Management of Hepatic Encephalopathy: An ISHEN Consensus. American Journal of Gastroenterology, 2020, 115, 989-1002.	0.4	87
28	Disordered purinergic signaling and abnormal cellular metabolism are associated with development of liver cancer in <i>Cd39/Entpd1</i> null Mice. Hepatology, 2013, 57, 205-216.	7.3	75
29	Assessment of a Deep Learning Model to Predict Hepatocellular Carcinoma in Patients With Hepatitis C Cirrhosis. JAMA Network Open, 2020, 3, e2015626.	5.9	75
30	Aspirin use is associated with lower indices of liver fibrosis among adults in the United States. Alimentary Pharmacology and Therapeutics, 2016, 43, 734-743.	3.7	74
31	Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography. American Journal of Gastroenterology, 2015, 110, 1298-1304.	0.4	69
32	Realâ€world effectiveness for 12 weeks of ledipasvir–sofosbuvir for genotype 1 hepatitis C: the Trio Health study. Journal of Viral Hepatitis, 2017, 24, 22-27.	2.0	69
33	Effect of increased alcohol consumption during COVIDâ€19 pandemic on alcoholâ€associated liver disease: A modeling study. Hepatology, 2022, 75, 1480-1490.	7.3	69
34	Incidence of and Risk Factors for Hepatic Encephalopathy in a Populationâ€Based Cohort of Americans With Cirrhosis. Hepatology Communications, 2019, 3, 1510-1519.	4.3	66
35	Cost-Effectiveness of Hepatocellular Carcinoma Surveillance: An Assessment of Benefits and Harms. American Journal of Gastroenterology, 2020, 115, 1642-1649.	0.4	66
36	Patientâ€reported outcomes in cirrhosis: A scoping review of the literature. Hepatology, 2018, 67, 2375-2383.	7.3	62

#	Article	IF	CITATIONS
37	Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a realâ€world cohort study. Hepatology, 2016, 64, 1893-1899.	7.3	61
38	Virtual Consultations Through the Veterans Administration SCANâ€ECHO Project Improves Survival for Veterans With Liver Disease. Hepatology, 2018, 68, 2317-2324.	7.3	61
39	Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. Journal of Viral Hepatitis, 2013, 20, 669-677.	2.0	60
40	A risk score to predict the development of hepatic encephalopathy in a populationâ€based cohort of patients with cirrhosis. Hepatology, 2018, 68, 1498-1507.	7.3	60
41	Frailty, Psychoactive Medications, and Cognitive Dysfunction Are Associated With Poor Patientâ∈Reported Outcomes in Cirrhosis. Hepatology, 2019, 69, 1676-1685.	7.3	55
42	Increased Morbidity and Mortality Associated with Falls Among Patients with Cirrhosis. American Journal of Medicine, 2018, 131, 645-650.e2.	1.5	53
43	Strategies to Reduce 30-Day Readmissions in Patients with Cirrhosis. Current Gastroenterology Reports, 2017, 19, 1.	2.5	52
44	Ethics Consultation at a Large Urban Public Teaching Hospital. Mayo Clinic Proceedings, 2010, 85, 433-438.	3.0	51
45	Building Effective Quality Improvement Programs for Liver Disease: A Systematic Review of Quality Improvement Initiatives. Clinical Gastroenterology and Hepatology, 2016, 14, 1256-1265.e3.	4.4	51
46	Weight loss results in significant improvements in quality of life for patients with nonalcoholic fatty liver disease: A prospective cohort study. Hepatology, 2016, 63, 1184-1189.	7.3	51
47	Psychoactive Medications Increase the Risk of Falls and Fall-related Injuries in Hospitalized Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2015, 13, 1670-1675.	4.4	48
48	Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score. PLoS ONE, 2016, 11, e0147237.	2.5	48
49	Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease. Gastroenterology Report, 2014, 2, 276-280.	1.3	46
50	Diagnosis of Minimal Hepatic Encephalopathy: A Systematic Review of Point-of-Care Diagnostic Tests. American Journal of Gastroenterology, 2018, 113, 529-538.	0.4	45
51	Hepatic encephalopathy impacts the predictive value of the Fried Frailty Index. American Journal of Transplantation, 2018, 18, 2566-2570.	4.7	45
52	Outcomes after hepatic encephalopathy in populationâ€based cohorts of patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2020, 51, 1397-1405.	3.7	45
53	Derivation and Internal Validation of a Clinical Prediction Tool for 30-Day Mortality in Lower Gastrointestinal Bleeding. American Journal of Medicine, 2017, 130, 601.e1-601.e8.	1.5	44
54	Early Versus Delayed Colonoscopy in Hospitalized Patients With Lower Gastrointestinal Bleeding. Journal of Clinical Gastroenterology, 2017, 51, 352-359.	2.2	44

#	Article	IF	CITATIONS
55	Model for Endâ€Stage Liver Diseaseâ€Lactate and Prediction of Inpatient Mortality in Patients With Chronic Liver Disease. Hepatology, 2020, 72, 1747-1757.	7.3	42
56	Hospital volume and mortality after transjugular intrahepatic portosystemic shunt creation in the United States. Hepatology, 2018, 67, 690-699.	7.3	40
57	The Quality and Outcomes of Care Provided to Patients with Cirrhosis by Advanced Practice Providers. Hepatology, 2020, 71, 225-234.	7.3	40
58	Incidence and Bedside Predictors of the First Episode of Overt Hepatic Encephalopathy in Patients With Cirrhosis. American Journal of Gastroenterology, 2020, 115, 2017-2025.	0.4	40
59	The clinical predictors of aetiology and complications among 173 patients presenting to the Emergency Department with oesophageal food bolus impaction from 2004–2014. Alimentary Pharmacology and Therapeutics, 2015, 42, 91-98.	3.7	38
60	Body composition predicts mortality and decompensation in compensated cirrhosis patients: A prospective cohort study. JHEP Reports, 2020, 2, 100061.	4.9	38
61	Gammaâ€Glutamyl Transferase (γâ€GT) – an old dog with new tricks?. Liver International, 2022, 42, 9-15.	3.9	38
62	Coagulopathy in cirrhosis – The role of the platelet in hemostasis. Journal of Hepatology, 2013, 59, 889-890.	3.7	37
63	Microbiome therapeutics for hepatic encephalopathy. Journal of Hepatology, 2021, 75, 1452-1464.	3.7	37
64	Effectiveness of 8―or 12â€weeks of ledipasvir and sofosbuvir in realâ€world treatmentâ€naÃ⁻ve, genotype 1 hepatitis C infected patients. Alimentary Pharmacology and Therapeutics, 2017, 46, 540-548.	3.7	36
65	Rebleeding vs Thromboembolism After Hospitalization for Gastrointestinal Bleeding in Patients on Direct Oral Anticoagulants. Clinical Gastroenterology and Hepatology, 2018, 16, 1893-1900.e2.	4.4	36
66	Direct costs of care for hepatocellular carcinoma in patients with hepatitis <scp>C</scp> cirrhosis. Cancer, 2016, 122, 852-858.	4.1	33
67	Interventions to improve physical function and prevent adverse events in cirrhosis. Gastroenterology Report, 2018, 6, 13-20.	1.3	33
68	The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: A real-world patient-reported outcomes study. JHEP Reports, 2019, 1, 154-161.	4.9	32
69	Acceptance and use of a smartphone application in cirrhosis. Liver International, 2020, 40, 1556-1563.	3.9	32
70	Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease. Liver International, 2016, 36, 1213-1220.	3.9	31
71	Patient Preferences for Hepatocellular Carcinoma Surveillance Parameters. Clinical Gastroenterology and Hepatology, 2022, 20, 204-215.e6.	4.4	31
72	Serum Ammonia is Associated With Transplant-free Survival in Hospitalized Patients With Acutely Decompensated Cirrhosis. Journal of Clinical Gastroenterology, 2016, 50, 345-350.	2.2	30

#	Article	IF	Citations
73	Bedside Measures of Frailty and Cognitive Function Correlate with Sarcopenia in Patients with Cirrhosis. Digestive Diseases and Sciences, 2019, 64, 3652-3659.	2.3	30
74	Opioid prescriptions are associated with hepatic encephalopathy in a national cohort of patients with compensated cirrhosis. Alimentary Pharmacology and Therapeutics, 2020, 51, 652-660.	3.7	30
75	Risk Factors for Adverse Outcomes in Patients Hospitalized With Lower Gastrointestinal Bleeding. Mayo Clinic Proceedings, 2015, 90, 1021-1029.	3.0	29
76	Low Likelihood of Intracranial Hemorrhage in Patients With Cirrhosis and Altered Mental Status. Clinical Gastroenterology and Hepatology, 2015, 13, 165-169.	4.4	29
77	Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis. Hepatology, 2019, 70, 403-409.	7.3	29
78	Osteoporosis in primary biliary cholangitis. World Journal of Gastroenterology, 2018, 24, 3513-3520.	3.3	29
79	Management of Pruritus in Primary Biliary Cholangitis: A Narrative Review. American Journal of Medicine, 2017, 130, 744.e1-744.e7.	1.5	28
80	Extensive testing or focused testing of patients with elevated liver enzymes. Journal of Hepatology, 2017, 66, 313-319.	3.7	28
81	Treatment of Fatigue in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 2019, 64, 2338-2350.	2.3	28
82	Limited Progress in Hepatorenal Syndrome (HRS) Reversal and Survival 2002–2018: A Systematic Review and Meta-Analysis. Digestive Diseases and Sciences, 2020, 65, 1539-1548.	2.3	26
83	Quality measures in HCC care by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology, 2022, 75, 1289-1299.	7.3	26
84	Contemporary Assessment of Hepatic Fibrosis. Clinics in Liver Disease, 2015, 19, 123-134.	2.1	25
85	A Longitudinal Study of Adenoma Detection Rate in Gastroenterology Fellowship Training. Digestive Diseases and Sciences, 2016, 61, 2831-2837.	2.3	25
86	Falls are common, morbid, and predictable in patients with cirrhosis. Journal of Hepatology, 2021, 75, 582-588.	3.7	25
87	Paraduodenal Pancreatitis: Clinical Performance of MR Imaging in Distinguishing from Carcinoma. Radiology, 2013, 269, 475-481.	7.3	24
88	Portopulmonary Hypertension: Imatinib as a Novel Treatment and the Emory Experience With this Condition. Transplantation Proceedings, 2009, 41, 1969-1971.	0.6	23
89	Consults for Conflict: The History of Ethics Consultation. Baylor University Medical Center Proceedings, 2013, 26, 417-422.	0.5	23
90	Systematic review and meta-analysis of third-line salvage therapy with infliximab or cyclosporine in severe ulcerative colitis. Annals of Gastroenterology, 2016, 29, 341-7.	0.6	23

#	Article	IF	CITATIONS
91	Challenge accepted: Confronting readmissions for our patients with cirrhosis. Hepatology, 2016, 64, 26-28.	7.3	23
92	Determinants and outcomes of adherence to recommendations from a multidisciplinary tumour conference for hepatocellular carcinoma. Hpb, 2014, 16, 1009-1015.	0.3	22
93	A Multicenter Study Into Causes of Severe Acute Liver Injury. Clinical Gastroenterology and Hepatology, 2019, 17, 1201-1203.	4.4	22
94	Low LDL-C and High HDL-C Levels Are Associated with Elevated Serum Transaminases amongst Adults in the United States: A Cross-sectional Study. PLoS ONE, 2014, 9, e85366.	2.5	21
95	Lowâ€fasting triglyceride levels are associated with nonâ€invasive markers of advanced liver fibrosis among adults in the United States. Alimentary Pharmacology and Therapeutics, 2015, 42, 106-116.	3.7	21
96	Optimizing medication management for patients with cirrhosis: Evidenceâ€based strategies and their outcomes. Liver International, 2018, 38, 1882-1890.	3.9	21
97	Nonhospice Palliative Care Within the Treatment of Endâ€Stage Liver Disease. Hepatology, 2020, 71, 2149-2159.	7.3	21
98	Appropriate and Potentially Inappropriate Medication Use in Decompensated Cirrhosis. Hepatology, 2021, 73, 2429-2440.	7.3	21
99	The Optimal Timing of Hepatitis C Therapy in Transplant Eligible Patients With Child B and C Cirrhosis. Transplantation, 2017, 101, 987-995.	1.0	20
100	Reduced Incidence of Hepatic Encephalopathy and Higher Odds of Resolution Associated With Eradication of HCV Infection. Clinical Gastroenterology and Hepatology, 2020, 18, 1197-1206.e7.	4.4	20
101	Systematic review: development of a consensus code set to identify cirrhosis in electronic health records. Alimentary Pharmacology and Therapeutics, 2022, 55, 645-657.	3.7	20
102	Review article: current and emerging therapies for the management of cirrhosis and its complications. Alimentary Pharmacology and Therapeutics, 2022, 55, 1099-1115.	3.7	20
103	Staging laparoscopy for proximal pancreatic cancer in a magnetic resonance imaging-driven practice: what's it worth?. Hpb, 2011, 13, 732-737.	0.3	19
104	Non-Operative Management of Right Posterior Sectoral Duct Injury Following Laparoscopic Cholecystectomy. Journal of Gastrointestinal Surgery, 2011, 15, 1237-1242.	1.7	19
105	Contemporary Epidemiology of Cirrhosis. Current Treatment Options in Gastroenterology, 2019, 17, 244-253.	0.8	19
106	Identifying Patients With Hepatic Encephalopathy Using Administrative Data in the ICD-10 Era. Clinical Gastroenterology and Hepatology, 2021, 19, 604-606.e1.	4.4	19
107	Assessment of National Organ Donation Rates and Organ Procurement Organization Metrics. JAMA Surgery, 2021, 156, 173.	4.3	18
108	Opioid and benzodiazepine prescription among patients with cirrhosis compared to other forms of chronic disease. BMJ Open Gastroenterology, 2019, 6, e000271.	2.7	18

#	Article	IF	CITATIONS
109	Patientâ€reported outcomes in HCC: A scoping review by the Practice Metrics Committee of the American Association for the Study of Liver Diseases. Hepatology, 2022, 76, 251-274.	7.3	18
110	A unique benign mucinous cystadenoma of the retroperitoneum: a case report and review of the literature. Archives of Gynecology and Obstetrics, 2010, 281, 167-169.	1.7	17
111	Estimated Association Between Organ Availability and Presumed Consent in Solid Organ Transplant. JAMA Network Open, 2019, 2, e1912431.	5.9	17
112	Protective effects of coffee consumption following liver transplantation for hepatocellular carcinoma in cirrhosis. Alimentary Pharmacology and Therapeutics, 2019, 49, 779-788.	3.7	17
113	Neurocognitive and Muscular Capacities Are Associated with Frailty in Adults with Cirrhosis.  Digestive Diseases and Sciences, 2020, 65, 3734-3743.	2.3	17
114	Cognitive Function, Sarcopenia, and Inflammation Are Strongly Associated with Frailty: A Framingham Cohort Study. American Journal of Medicine, 2021, 134, 1530-1538.	1.5	17
115	Viscoelastic Testing Prior to Non-surgical Procedures Reduces Blood Product Use Without Increasing Bleeding Risk in Cirrhosis. Digestive Diseases and Sciences, 2022, 67, 5290-5299.	2.3	17
116	The Overuse of Serum Ceruloplasmin Measurement. American Journal of Medicine, 2013, 126, 926.e1-926.e5.	1.5	16
117	The efficacy and safety profile of albumin administration for patients with cirrhosis at high risk of hepatorenal syndrome is dose dependent. Gastroenterology Report, 2015, 3, 216-221.	1.3	16
118	The impact of race and ethnicity on mortality and healthcare utilization in alcoholic hepatitis: a cross-sectional study. BMC Gastroenterology, 2016, 16, 129.	2.0	16
119	Coordination of Care Is Associated With Survival and Health Care Utilization in a Population-Based Study of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology, 2020, 18, 2340-2348.e3.	4.4	16
120	Automated Measurements of Muscle Mass Using Deep Learning Can Predict Clinical Outcomes in Patients With Liver Disease. American Journal of Gastroenterology, 2020, 115, 1210-1216.	0.4	16
121	Risk and Outcome of Venous and Arterial Thrombosis in Patients With Cirrhosis: A Danish Nationâ€wide Cohort Study. Hepatology, 2021, 74, 2725-2734.	7.3	16
122	Vibration-controlled transient elastography. Current Opinion in Gastroenterology, 2015, 31, 192-198.	2.3	15
123	Hepatocellular carcinoma surveillance, early detection and survival in a privately insured US cohort. Liver International, 2020, 40, 947-955.	3.9	15
124	Effective Mentorship as a Means to Recruit, Retain, and Promote Underrepresented Minorities in Academic Gastroenterology and Hepatology. American Journal of Gastroenterology, 2021, 116, 1110-1113.	0.4	15
125	Alcohol Policies and Alcohol-related Liver Disease Mortality. Gastroenterology, 2021, 161, 350-352.	1.3	15
126	Serum Ammonia in Cirrhosis: Clinical Impact of Hyperammonemia, Utility of Testing, and National Testing Trends. Clinical Therapeutics, 2022, 44, e45-e57.	2.5	15

#	Article	IF	CITATIONS
127	Doctors on Display: The Evolution of Television's Doctors. Baylor University Medical Center Proceedings, 2010, 23, 393-399.	0.5	14
128	Does Karnofsky Performance Status of Patients With Cirrhosis onÂthe Transplant Waitlist Meet the Eyeball Test?. Clinical Gastroenterology and Hepatology, 2016, 14, 1196-1198.	4.4	14
129	Comparison of Vascular Plugs and Pushable Coils for Variceal Embolization After TIPS. American Journal of Roentgenology, 2017, 208, 650-655.	2.2	14
130	Dos and Don'ts in the Management of Cirrhosis: A View from the 21st Century. American Journal of Gastroenterology, 2018, 113, 927-931.	0.4	14
131	Why Do Individuals with Cirrhosis Fall? A Mechanistic Model for Fall Assessment, Treatment, and Research. Digestive Diseases and Sciences, 2019, 64, 316-323.	2.3	14
132	Coffee Consumption Is Associated With Lower Liver Stiffness: A Nationally Representative Study. Clinical Gastroenterology and Hepatology, 2022, 20, 2032-2040.e6.	4.4	14
133	The Morbidity and Mortality Conference in Gastroenterology and Hepatology: An Important Cornerstone of Patient Safety and Optimal Care. Gastroenterology, 2016, 150, 19-23.	1.3	13
134	Before or After Transplantation? A Review of the Cost Effectiveness of Treating Waitlisted Patients With Hepatitis C. Transplantation, 2017, 101, 933-937.	1.0	13
135	Frailty and Outcomes After Liver Transplantation. Current Transplantation Reports, 2019, 6, 1-6.	2.0	13
136	#LiverTwitter: An Emerging Tool for Liver Education and Research. Hepatology Communications, 2020, 4, 1229-1233.	4.3	13
137	Women on the liver transplantation waitlist are at increased risk of hospitalization compared to men. World Journal of Gastroenterology, 2018, 25, 980-988.	3.3	13
138	An MRI-Driven Practice: a New Perspective on MRI for the Evaluation of Adenocarcinoma of the Head of the Pancreas. Journal of Gastrointestinal Surgery, 2010, 14, 1292-1297.	1.7	12
139	Preventing and Treating Acute Kidney Injury Among Hospitalized Patients with Cirrhosis and Ascites: A Narrative Review. American Journal of Medicine, 2016, 129, 461-467.	1.5	12
140	Understanding and Reducing Ceruloplasmin Overuse with a Decision Support Intervention for Liver Disease Evaluation. American Journal of Medicine, 2016, 129, 115.e17-115.e22.	1.5	12
141	A Multicenter Evaluation of Adherence to 4 Major Elements of the Baveno Guidelines and Outcomes for Patients With Acute Variceal Hemorrhage. Journal of Clinical Gastroenterology, 2018, 52, 172-177.	2.2	12
142	Optimizing the use of twitter for research dissemination: The "Three Facts and a Story― randomized-controlled trial. Journal of Hepatology, 2021, 75, 271-274.	3.7	12
143	Isotretinoin Laboratory Monitoring in Acne Treatment. JAMA Dermatology, 2022, 158, 942.	4.1	12
144	A Decision Support Tool to Reduce Overtesting for Ceruloplasmin and Improve Adherence With Clinical Guidelines. JAMA Internal Medicine, 2015, 175, 1561.	5.1	11

#	Article	IF	Citations
145	The Changing Role of Sodium Management in Cirrhosis. Current Treatment Options in Gastroenterology, 2016, 14, 274-284.	0.8	11
146	Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease. Journal of Clinical Gastroenterology, 2018, 52, 444-451.	2.2	11
147	Comprehensive Healthâ€State Utilities in Contemporary Patients With Cirrhosis. Hepatology Communications, 2020, 4, 852-858.	4.3	11
148	How Do Patients With Cirrhosis and Their Caregivers Learn About and Manage Their Health? A Review and Qualitative Study. Hepatology Communications, 2021, 5, 168-176.	4.3	11
149	A Telemonitoring Intervention for Cirrhotic Ascites Management Is Cost-Saving. Digestive Diseases and Sciences, 2022, 67, 854-862.	2.3	11
150	The Future of Quality Improvement for Cirrhosis. Liver Transplantation, 2021, 27, 1479-1489.	2.4	11
151	An Electronic Decision Support Intervention Reduces Readmissions for Patients With Cirrhosis. American Journal of Gastroenterology, 2022, 117, 491-494.	0.4	11
152	Pickle Juice Intervention for Cirrhotic Cramps Reduction: The PICCLES Randomized Controlled Trial. American Journal of Gastroenterology, 2022, 117, 895-901.	0.4	11
153	Suboptimal Implementation of Evidence-based Therapy for Acute Variceal Hemorrhage: A Systematic Review of Observational Studies. Clinical Gastroenterology and Hepatology, 2017, 15, 1373-1381.e7.	4.4	10
154	Outcomes of Patients With Cirrhosis Undergoing Orthopedic Procedures. Journal of Clinical Gastroenterology, 2019, 53, e356-e361.	2.2	10
155	Animal Naming Test Is Associated With Poor Patient-Reported Outcomes and Frailty in People With and Without Cirrhosis: A Prospective Cohort Study. Clinical and Translational Gastroenterology, 2022, 13, e00447.	2.5	10
156	Direct costs of first-generation protease inhibitors for the treatment of genotype 1 chronic hepatitis C viral infection. Journal of Viral Hepatitis, 2015, 22, 974-976.	2.0	9
157	High Glasgow Blatchford Score at admission is associated with recurrent bleeding after discharge for patients hospitalized with upper gastrointestinal bleeding. Endoscopy, 2015, 48, 9-15.	1.8	9
158	Factors That Affect Results of Psychometric Tests to Identify Patients With Minimal Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology, 2018, 16, 1836-1838.	4.4	9
159	Deprescribing medications that may increase the risk of hepatic encephalopathy: A qualitative study of patients with cirrhosis and their doctors. United European Gastroenterology Journal, 2021, 9, 193-202.	3.8	9
160	Comparison of Seven Noninvasive Models for Predicting Decompensation and Hospitalization in Patients with Cirrhosis. Digestive Diseases and Sciences, 2021, 66, 4508-4517.	2.3	9
161	The need for antibiotic stewardship and treatment standardization in the care of cirrhotic patients with spontaneous bacterial peritonitis – a retrospective cohort study examining the effect of ceftriaxone dosing. F1000Research, 2014, 3, 57.	1.6	9
162	Racial and ethnic disparities in rifaximin use and subspecialty referrals for patients with hepatic encephalopathy in the United States. Journal of Hepatology, 2022, 77, 377-382.	3.7	9

#	Article	IF	Citations
163	Secondary Kwashiorkor: A Rare Complication of Gastric Bypass Surgery. American Journal of Medicine, 2015, 128, e1-e2.	1.5	8
164	Primary biliary cholangitis: new treatments for an old disease. Frontline Gastroenterology, 2017, 8, 29-36.	1.8	8
165	Nonalcoholic fatty liver disease, metabolic syndrome, and the fight that will define clinical practice for a generation of hepatologists. Hepatology, 2018, 67, 1657-1659.	7.3	8
166	The Pharmacologic Management of Osteoporosis in Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis. Journal of Clinical Densitometry, 2020, 23, 223-236.	1.2	8
167	Low-Value Levels: Ammonia Testing Does Not Improve the Outcomes of Overt Hepatic Encephalopathy. American Journal of Gastroenterology, 2020, 115, 685-686.	0.4	8
168	Sugar-sweetened Beverages Are Associated With Increased Liver Stiffness and Steatosis Among Apparently Healthy Adults in the United States. Clinical Gastroenterology and Hepatology, 2022, 20, 959-961.e1.	4.4	8
169	International Classification of Diseases Codes are Useful in Identifying Cirrhosis in Administrative Databases. Digestive Diseases and Sciences, 2022, 67, 2107-2122.	2.3	8
170	Teaching Quality Improvement on the Wards: How We Do It. MedEdPORTAL: the Journal of Teaching and Learning Resources, 0, , .	1.2	8
171	Nonselective Betaâ€Blockers in Portal Hypertension: Why, When, and How?. Clinical Liver Disease, 2022, 19, 118-123.	2.1	8
172	Low Yield and Utilization of Confirmatory Testing in a Cohort of Patients with Liver Disease Assessed for Alpha-1 Antitrypsin Deficiency. Digestive Diseases and Sciences, 2015, 60, 1589-1594.	2.3	7
173	A Standardized Assessment of Functional Disability Predicts 1-year Mortality in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites. Journal of Clinical Gastroenterology, 2016, 50, 75-79.	2.2	7
174	Constitutional Challenges to Liver Transplant Policy. Transplantation, 2019, 103, e378-e381.	1.0	7
175	A Prospective, Blinded Assessment of Ammonia Testing Demonstrates Low Utility Among Front-Line Clinicians. Clinical Gastroenterology and Hepatology, 2022, 20, e895-e896.	4.4	7
176	Inpatient Gastroenterology Consultation and Outcomes of Cirrhosis-Related Hospitalizations in Two Large National Cohorts. Digestive Diseases and Sciences, 2022, 67, 2094-2104.	2.3	7
177	The emotional burden of caregiving for patients with cirrhosis. Hepatology Communications, 2022, 6, 2827-2835.	4.3	7
178	The Use of Administrative Data to Investigate the Population Burden of Hepatic Encephalopathy. Journal of Clinical Medicine, 2020, 9, 3620.	2.4	6
179	Do Nutritional Interventions Improve the Outcomes of Patients with Cirrhosis and Ascites: a Systematic Review of Randomized Trials. Current Hepatology Reports, 2020, 19, 71-77.	0.9	6
180	The incidence and outcome of postoperative hepatic encephalopathy in patients with cirrhosis. United European Gastroenterology Journal, 2021, 9, 672-680.	3.8	6

#	Article	IF	CITATIONS
181	Strategies to Improve Video Visit Use in Persons With Liver Disease. Gastroenterology, 2021, 161, 1080-1084.e2.	1.3	6
182	Association of chronic liver disease with cognition and brain volumes in two randomized controlled trial populations. Journal of the Neurological Sciences, 2022, 434, 120117.	0.6	6
183	Hepatocellular Carcinoma-Related Mortality in the USA, 1999–2018. Digestive Diseases and Sciences, 2022, 67, 4100-4111.	2.3	6
184	Deprescribing zolpidem reduces falls and fractures in patients with cirrhosis. JHEP Reports, 2022, 4, 100478.	4.9	6
185	Evaluation of Hemostatic Factors in Patients Undergoing Major Hepatic Resection and Other Major Abdominal Surgeries. American Surgeon, 2011, 77, 1188-1193.	0.8	5
186	Factors Affecting Adherence to a Quality Improvement Checklist on an Inpatient Hepatology Service. Baylor University Medical Center Proceedings, 2014, 27, 100-102.	0.5	5
187	Who Orders a Head CT?. Journal of Clinical Gastroenterology, 2017, 51, 632-638.	2.2	5
188	Hospitalâ€level balloon tamponade use is associated with increased mortality for all patients presenting with acute variceal haemorrhage. Liver International, 2018, 38, 477-483.	3.9	5
189	Design and rationale of a randomized–controlled trial of home-delivered meals for the management of symptomatic ascites: the SALTYFOOD trial. Gastroenterology Report, 2019, 7, 146-149.	1.3	5
190	Causes and Rates of 30-Day Readmissions After Transjugular Intrahepatic Portosystemic Shunts. American Journal of Roentgenology, 2020, 215, 235-241.	2.2	5
191	A 78-Year-Old Man with Acute Myeloid Leukemia (AML) and Acute Renal Failure. American Journal of Case Reports, 2014, 15, 364-367.	0.8	5
192	Rate of Successful Extubation in Mechanically Ventilated Patients with Cirrhosis and Hepatic Coma. Digestive Diseases and Sciences, 2022, , 1.	2.3	5
193	Contemporary management of pain in cirrhosis: Toward precision therapy for pain. Hepatology, 2023, 77, 290-304.	7.3	5
194	Current knowledge of antibiotic prophylaxis guidelines regarding GI open-access endoscopic procedures is inadequate. Gastrointestinal Endoscopy, 2015, 82, 268-275.e7.	1.0	4
195	Early readmissions after liver transplantation and the power of quality improvement. Liver Transplantation, 2016, 22, 717-719.	2.4	4
196	How to Succeed in Research During Fellowship: What the Trainee Needs To Do (and Needs From the) Tj ETQq0	0 0 <sub>[g</sub> BT /0	Overlock 10 Tf
197	Embracing early discharge in patients with lower gastrointestinal bleeding. The Lancet Gastroenterology and Hepatology, 2017, 2, 620-621.	8.1	4
198	Is Exercise Beneficial and Safe in Patients with Cirrhosis and Portal Hypertension?. Current Hepatology Reports, 2018, 17, 175-183.	0.9	4

#	Article	IF	CITATIONS
199	Hepatic encephalopathy and traffic accidents: Vigilance is needed!. Journal of Hepatology, 2019, 70, 590-592.	3.7	4
200	How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?. Annals of Internal Medicine, 2019, 171, 199.	3.9	4
201	ERCP in Patients With Cirrhosis: "Risky Business―Or "Just Do it�. American Journal of Gastroenterology, 2019, 114, 19-20.	0.4	4
202	Medically tailored meals for the management of symptomatic ascites: the SALTYFOOD pilot randomized clinical trial. Gastroenterology Report, 2020, 8, 453-456.	1.3	4
203	Applying Administrative Dataâ€Based Coding Algorithms for Frailty in Patients With Cirrhosis. Liver Transplantation, 2021, 27, 1401-1411.	2.4	4
204	Nonalcoholic Fatty Liver Disease Natural History: Role of Mathematical Modeling. Clinical Gastroenterology and Hepatology, 2023, 21, 280-282.	4.4	4
205	Clinical pearls regarding Prinzmetal's angina complicated by cardiac arrest – management during therapeutic hypothermia. International Journal of Cardiology, 2012, 159, 55-57.	1.7	3
206	Reply to: "Circulating platelet derived microparticles are not increased in patients with cirrhosis― Journal of Hepatology, 2013, 59, 913.	3.7	3
207	Multicenter Study Assessing Physician Recommendations Regarding the Continuation of Aspirin and/or NSAIDs Prior to Gastrointestinal Endoscopy. Digestive Diseases and Sciences, 2015, 60, 3234-3241.	2.3	3
208	Cost Saving or Cost Effective? Unanswered Questions in the Screening of Patients With Nonalcoholic Fatty Liver Disease. Hepatology Communications, 2019, 3, 1293-1295.	4.3	3
209	Impact of Inpatient Attending Specialty and Gastroenterology Consultation on Quality of Care of Patients Hospitalized with Decompensated Cirrhosis. American Journal of Medicine, 2021, 134, 1270-1277.e2.	1.5	3
210	Prevalence of High Liver Stiffness and a Screening Strategy Using the SODAâ€2B Score Among US Adults. Hepatology Communications, 2022, 6, 898-909.	4.3	3
211	Evaluation of hemostatic factors in patients undergoing major hepatic resection and other major abdominal surgeries. American Surgeon, 2011, 77, 1188-93.	0.8	3
212	Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans. Digestive Diseases and Sciences, 2022, 67, 5327-5335.	2.3	3
213	Symptomatic Bile Duct Hamartomas: Surgical Management in an MRI Driven Practice. Journal of Gastrointestinal Surgery, 2010, 14, 1265-1270.	1.7	2
214	Rifaximin for the prevention of readmissions for patients with hepatic encephalopathy – the price is right. Liver International, 2016, 36, 1252-1254.	3.9	2
215	Chest Pain Suggestive of a Life-Threatening Condition: A Department of Medicine Morbidity and Mortality Conference. Psychosomatics, 2016, 57, 89-96.	2.5	2
216	Tackling 30-Day Readmissions in Patients with Cirrhosis. Current Hepatology Reports, 2018, 17, 8-14.	0.9	2

#	Article	IF	CITATIONS
217	Reducing the Burden of False-Positive Tests: It Is Time to Optimize Diagnostic Testing for Undifferentiated Conditions. Mayo Clinic Proceedings, 2019, 94, 1143-1146.	3.0	2
218	Transforming Chief Residents into Chief Scholars. Medical Science Educator, 2019, 29, 1135-1139.	1.5	2
219	Driving in the dark: cirrhosis in young adults. The Lancet Gastroenterology and Hepatology, 2019, 4, 189-190.	8.1	2
220	A Trial of Ornithine Phenylacetate and the Arc of Ammonia's History in the Management of Overt Hepatic Encephalopathy. Clinical Gastroenterology and Hepatology, 2021, 19, 2493-2495.	4.4	2
221	Social Support Does Not Modify the Risk of Readmission for Patients with Decompensated Cirrhosis. Digestive Diseases and Sciences, 2021, 66, 1855-1861.	2.3	2
222	A Claimsâ€Based Frailty Risk Score Is Associated With Hospitalization for Acuteâ€onâ€Chronic Liver Failure: But Is It Frailty?. Liver Transplantation, 2021, 27, 9-11.	2.4	2
223	How Would You Manage This Patient With Nonalcoholic Fatty Liver Disease?. Annals of Internal Medicine, 2019, 171, 862.	3.9	2
224	Identifying Ascites in Patients with Cirrhosis Using Administrative Codes and Diuretic Use: A Multicenter Study. Digestive Diseases and Sciences, 2022, 67, 4695-4701.	2.3	2
225	A Two-Step Algorithm for the Noninvasive Identification of Candidates for Nonalcoholic Steatohepatitis Clinical Trials: The APRI-FAST. Clinical Gastroenterology and Hepatology, 2023, 21, 1652-1653.	4.4	2
226	The aspartate aminotransferase-to-platelet ratio and the evaluation of non-alcoholic fatty liver disease. Gastroenterology Report, 2014, 2, 326-327.	1.3	1
227	Predictors of Negative Intraoperative Findings at Emergent Laparotomy in Patients with Cirrhosis. Journal of Gastrointestinal Surgery, 2014, 18, 1777-1783.	1.7	1
228	Immunosuppressive Therapy in Immune-Mediated Liver Disease in the Non-Transplanted Patient. Pharmaceuticals, 2014, 7, 18-28.	3.8	1
229	Contemporary Perspectives on the Pathophysiology and Management of Hepatic Hydrothorax. Current Hepatology Reports, 2015, 14, 212-218.	0.9	1
230	Lactulose vs Polyethylene Glycol for Treatment of Hepatic Encephalopathy. JAMA Internal Medicine, 2015, 175, 867.	5.1	1
231	Role of Noninvasive Fibrosis Methods in Management of Chronic Hepatitis B Virus. Current Hepatology Reports, 2016, 15, 220-229.	0.9	1
232	Optimizing the Outcomes Associated With Spontaneous Bacterial Peritonitis. Journal of Clinical Gastroenterology, 2017, 51, 191-194.	2.2	1
233	Editorial: the impact of steatosis on liver stiffness quantification is minimal. Alimentary Pharmacology and Therapeutics, 2018, 47, 1416-1417.	3.7	1
234	Towards patient-centred and cost-effective care for patients with cirrhosis and ascites. The Lancet Gastroenterology and Hepatology, 2018, 3, 75-76.	8.1	1

#	Article	IF	CITATIONS
235	Hepatic Encephalopathy: A Diagnosis for the Individual but an Experience for the Household. Clinical and Translational Gastroenterology, 2020, 11, e00181.	2.5	1
236	We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can. Pharmacoeconomics, 2020, 38, 427-429.	3.3	1
237	Attacking Alcoholâ€Related Liver Disease by Taxing Alcohol Sales. Alcoholism: Clinical and Experimental Research, 2021, 45, 51-53.	2.4	1
238	Reply. Clinical Gastroenterology and Hepatology, 2021, 19, 2457-2458.	4.4	1
239	The Role of Advanced Practice Providers in the Care of Nonalcoholic Fatty Liver Disease. Clinical Therapeutics, 2021, 43, 518-523.	2.5	1
240	Severe Hepatic Steatosis by Controlled Attenuation Parameter Predicts Quality of Life Independent of Fibrosis. Digestive Diseases and Sciences, 2021, , 1.	2.3	1
241	Nondirected Testing for Inpatients With Severe Liver Injury. Journal of Hospital Medicine, 2017, 12, 184-187.	1.4	1
242	Frailty and Sarcopenia in theÂCritically Ill Patient with Cirrhosis. , 2020, , 141-160.		1
243	Deciphering the Cirrhotic Patient's Present Status: The Overlap Between Physical Frailty, Disability, and Sarcopenia. , 2020, , 25-32.		1
244	Falls are common, morbid, and predictable among people with cirrhosis. European Journal of Gastroenterology and Hepatology, 2021, 33, e1101-e1102.	1.6	1
245	Response to Gupta et al. Regarding Non-operative Management of Right Posterior Sectoral Duct Injury. Journal of Gastrointestinal Surgery, 2011, 15, 2125-2126.	1.7	0
246	Letter in Response to the Recently Published Review: Hyponatremia in Cirrhosis and End-Stage Liver Disease—Treatment with the Vasopressin V2-Receptor Antagonist Tolvaptan. Digestive Diseases and Sciences, 2013, 58, 889-890.	2.3	0
247	Letter: seasonality in eosinophilic oesophagitis and food bolus obstruction – what about recurrent episodes? – Authors' reply. Alimentary Pharmacology and Therapeutics, 2015, 42, 937-937.	3.7	O
248	Giant Cystic Arteriovenous Malformation of the Mesentery and the Role of Cross-Sectional Imaging in Occult Gastrointestinal Bleeding. ACG Case Reports Journal, 2015, 2, 158-160.	0.4	0
249	The Reply. American Journal of Medicine, 2016, 129, e263.	1.5	0
250	Letter: would aspirin alleviate fibrosis in alcoholic liver disease? Authors' reply. Alimentary Pharmacology and Therapeutics, 2016, 44, 209-210.	3.7	0
251	Reply to: "Should anti-LKM1 be routine for work-up of elevated liver enzymes?― Journal of Hepatology, 2017, 67, 418-419.	3.7	0
252	Reply. Hepatology, 2018, 67, 1637-1638.	7.3	0

#	Article	IF	CITATIONS
253	Reply. Hepatology, 2018, 67, 1636-1636.	7.3	О
254	Commentary. Clinical Chemistry, 2019, 65, 961-961.	3.2	0
255	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 1006.	4.4	O
256	Prescription opioid use is common and associated with worse clinical outcomes in individuals with chronic liver disease. GastroHep, 2020, 2, 13-21.	0.6	0
257	Letter: are opioid prescriptions associated with hepatic encephalopathy in patients with compensated cirrhosis? Authors' reply. Alimentary Pharmacology and Therapeutics, 2020, 51, 743-744.	3.7	O
258	Baffled by NAFLD: The Horse Might Be Out of the Barn but Should Not Take Us for a Ride. American Journal of Managed Care, 2021, 27, 364-365.	1.1	0
259	Reply to: "We need to talk about #livertwitter― Journal of Hepatology, 2021, 75, 1240-1241.	3.7	O
260	Finding Common Ground With Our MASQs Off. American Journal of Gastroenterology, 2021, 116, 837-837.	0.4	0
261	An Assessment of Ineligible Donor Use in Solid Organ Transplant. Transplantation, 2022, Publish Ahead of Print, .	1.0	O
262	Reply. Clinical Gastroenterology and Hepatology, 2021, , .	4.4	0
263	OUP accepted manuscript. Gastroenterology Report, 2022, 10, goac015.	1.3	0
264	Falls are Common, Morbid, and Predictable among People with Cirrhosis European Journal of Gastroenterology and Hepatology, 2021, 33, e1101-e1102.	1.6	0
265	Pharmacistâ€led educational interventions involving the "hidden―patient in cirrhosis—Caregivers. Hepatology Communications, 2022, 6, 3283-3283.	4.3	O